Prescription Drug Abuse (Not Dependent) Clinical Trial
Official title:
A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan
The purpose of this study is to assess the abuse potential of study drug lasmiditan.
Lasmiditan will be compared to a marketed benzodiazepine, alprazolam (positive control), as
well as to placebo (dummy substance that looks like lasmiditan or alprazolam without any
active drug) to determine the potential for drug abuse. The dosages will be in tablet form
and will be taken orally (by mouth).
This study will last about 55 days, including screening. Screening will occur within 28 days
prior to qualification phase.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03648684 -
Examining Expectancy Challenges to Prevent Nonmedical Prescription Stimulant Use
|
N/A | |
Completed |
NCT03947749 -
Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
|
||
Active, not recruiting |
NCT03129334 -
Preventing Prescription Drug Abuse in Middle School Students
|
N/A | |
Completed |
NCT04069403 -
An Opioid Prescribing Nudge
|
N/A | |
Completed |
NCT03612713 -
Influence of Medication on Functional Connectivity
|
Early Phase 1 | |
Completed |
NCT03936985 -
Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
|
||
Recruiting |
NCT04885166 -
Preventing Prescription Stimulant Diversion and Medication Misuse Via a Web-Based Simulation Intervention
|
N/A | |
Completed |
NCT03165175 -
Mobile Application for Prescription Drug-Abuse Education (MAPDE)
|
N/A | |
Active, not recruiting |
NCT03219190 -
A High School Program for Preventing Prescription Drug Abuse
|
N/A |